tbuckley/cabot-search huggingface dataset:
TESTING THE VALIDITY OF PERSONALITY PROFILES IN PSYCHOSOMATIC ILLNESSES
Authors: FLOYD O. RING
Journal: American Journal of Psychiatry (1957)

Persons with some illnesses can be picked out from those with others with a good percentage of accuracy by personality interview study alone. Some of the personality profiles as described by various investigators (as interpreted and/or perhaps modified by the author) are valid for these illnesses. More concrete, conclusive, and objective evidence of the relationship between personality profiles and somatic illnesses is demonstrated. These personality profiles precede the onset of illness. There are some determining factors associated with certain personalities which make that individual more susceptible to certain illnesses and more resistive to others. Personality studies have been demonstrated to be a sensitive indicator that certain illnesses might be present even when not otherwise suspected. Treatment and preventive measures should be improved when these factors are better established. Personality patterns may determine whether an illness will develop. They may also influence its progress. Personality studies can be a useful prognostic tool. An extensive and closely coordinated study employing the psychiatrist, neurologist, physiologist, endocrinologist, biochemist, pathologist, and internist should be made to fill gaps in our knowledge of the psyche, the soma, and the inter-relationship between mind and body.
Demeclocycline in the treatment of the syndrome of inappropriate secretion of antidiuretic hormone.
Authors: W H Perks, E H Walters, I P Tams, K Prowse
Journal: Thorax (1979)

Fourteen patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) have been treated with demethylchlortetracycline (demeclocycline) 1200 mg daily. In 12 patients the underlying lesion was malignant. The serum sodium returned to normal (greater than 135 mmol/l) in all patients after a mean of 8.6 days (SD +/- 5.3 days). Blood urea rose significantly from the pretreatment level of 4.2 +/- 2.3 mmol/l to 10.1 +/- 5.1 mmol/l at ten days (P less than 0.001). The average maximum blood urea was 13.4 +/- 6.8 mmol/l. In four patients the urea rose above 20 mmol/l, and in two of these demecyocycline was discontinued because of thie rise. The azotaemia could be attributed to a combination of increased urea producation and a mild specific drug-induced nephrotoxicity. Discontinuation of demeclocycline in six patients led to a fall in serum sodium, in one case precipitously, and return of the urea towards normal levels. Demeclocycline appears therefore to be an effective maintenance treatment of SIADH, and the azotaemia that occurs is reversible and probably dose dependent.
Ascending Aorta to Right Pulmonary Artery Anastomosis
Authors: MILTON J. REITMAN, FRANK M. GALIOTO, GALAL M. EL-SAID, DENTON A. COOLEY, GRADY L. HALLMAN, DAN G. MCNAMARA
Journal: Circulation (1974)

An intrapericardial ascending aorta-to-right pulmonary artery anastomosis was performed in 123 patients with cyanotic congenital heart disease associated with pulmonary stenosis or atresia during the eight year period from 1964 through 1971. While there were 20 early postoperative deaths (16%), 90% (93 patients) of the 103 survivors were symptomatically improved. In the postoperative evaluation, 74 patients (72% of the survivors) returned for follow-up examination, which included cardiac catheterization in 57. The anastomosis was nonfunctioning in ten (13.5%) of these 74 patients and in an additional 13 (17.5%) patients, clinically silent right pulmonary artery stenosis was demonstrated angiographically at the anastomosis site. Clinical improvement had been maintained in the 64 patients with an open anastomosis (audible continuous murmur or angiographically demonstrated patency) including the 13 patients with acquired pulmonary stenosis at the operative site. Persistent right pulmonary artery stenosis was demonstrated in nine of the 14 patients who had cardiac catheterization after intracardiac repair of the congenital heart defect and closure of the anastomosis, but this was insignificant in four of these nine. The ascending aorta-to-right pulmonary artery anastomosis provides symptomatic improvement for most patients with cyanotic congenital heart disease associated with pulmonary stenosis but may produce right pulmonary artery obstruction requiring attention at the time of total intracardiac repair.
Spectrum and Outcome of Reoperations After the Ross Procedure
Authors: John M. Stulak, Harold M. Burkhart, Thoralf M. Sundt, Heidi M. Connolly, Rakesh M. Suri, Hartzell V. Schaff, Joseph A. Dearani
Journal: Circulation (2010)

Proposed advantages to the Ross procedure included presumed increased freedom from reoperation and simpler reoperation for pulmonary conduit replacement if needed. It is increasingly apparent, however, that reoperations are frequent after the Ross procedure and that when required, they may be more complex than previously thought.Between September 1991 and August 2008, 56 patients underwent reoperation at our institution after a Ross procedure performed by ourselves (n=13) or elsewhere (n=43). Median age at first reoperation at our institution was 26 years (range 1 to 69 years). The 4 most common indications for reoperation were isolated autograft (neoaortic) regurgitation in 11 cases (20), isolated pulmonary conduit regurgitation/stenosis in 9 (16), combined autograft regurgitation/dilatation in 8 (14), and combined autograft regurgitation and pulmonary conduit regurgitation/stenosis in 6 (11). A total of 144 procedures were performed in these 56 patients during first reoperation at our institution. The autograft valve required replacement in 21 cases (38) and aortic root replacement in 21 (38), with ascending aortic/arch reconstruction in 13 (23) and mitral valve surgery in 5 (9). The pulmonary valve was replaced in 33 cases (59) and the tricuspid valve was repaired/replaced in 10 (18). Early mortality was 1.8 (1 of 56 patients), and morbidity included 6 patients with respiratory failure and 3 who required postcardiotomy extracorporeal membrane oxygenation. There were 4 late deaths during the median follow-up of 8 months (range 1 to 179 months).A broad spectrum of complex reoperations may be required after the Ross procedure. Patients and family members considering the procedure should be informed of the potential for associated morbidity should reoperation be necessary.
Hepatic ischemic preconditioning in mice is associated with activation of NF-κB, p38 kinase, and cell cycle entry
Authors: Narci Teoh, Aileen Dela Pena, Geoffrey Farrell
Journal: Hepatology (2002)

A brief period of hepatic ischemia protects the liver against subsequent ischemia-reperfusion (IR) injury, but the mechanism of such preconditioning is poorly understood. We examined whether preconditioning activated nuclear factor kappa B (NF-κB), the stress-activated protein kinases (SAPK), c-Jun N-terminal kinase-1 (JNK-1) and p38, and entry into the cell cycle. We used a murine model of partial hepatic ischemia. Preconditioning was performed by clamping the vasculature for 2 to 20 minutes, and allowing reperfusion for 10 minutes before 90-minute ischemia or IR. As assessed by serum alanine aminotransferase (ALT) levels and liver histology, preconditioning periods of 5 and 10 minutes were highly protective against IR injury, whereas 2-, 15-, and 20-minute intervals were ineffective. Preconditioning was associated with entry of hepatocytes into the cell cycle within 2 hours of subsequent IR, as indicated by proliferating cell nuclear antigen (PCNA) nuclear staining, induction of cyclin D1 and numerous mitotic figures; in the absence of preconditioning, such changes were not seen until 24 hours. Preconditioning increased nuclear binding of NF-κB within 30 minutes of the subsequent ischemic interval, paralleled by degradation of inhibitory (binding) protein for NF-κB (IκBα). Ischemic preconditioning also activated p38 kinase and JNK-1, which are known to converge on cyclin D1 regulation. The protective effect of the preconditioning regimen was more closely associated with p38 kinase than JNK-1 activation. In conclusion, the hepatoprotective effects of ischemic preconditioning are associated with activation of NF-κB and SAPKs that are associated with entry of hepatocytes into the cell cycle, a critical biological effect that favors survival of the liver against ischemic and IR injury.
Fibrin Degradation Products and the Role of Coagulation in "Persistent" Glomerulonephritis
Authors: PHISIT CHIRAWONG
Journal: Annals of Internal Medicine (1971)

In 46 patients with persistent glomerulonephritis, fibrin degradation products have been measured at the time of a renal biopsy. These products were present in the serum in all patients with glomerulonephritis. In 58.7% of patients the level of fibrin degradation products was elevated above the highest level detected in a normal adult. Within the group with diffuse proliferative lesions there was also a significant difference between the levels in patients with mild proliferative glomerulonephritis and those with mesangiocapillary (membranoproliferative) glomerulonephritis and fibrin and crescent formation. There was a high degree of correlation between increased levels and a blind histological grading of activity of the glomerular lesion (P < 0.005). Demonstration of fibrin by immunofluorescent methods and electron microscopy also appeared to correlate with elevated levels of fibrin degradation products. The role of the coagulation process in the pathogenesis of progressive glomerular lesions and the rationale for the use of antithrombotic and anticoagulant drugs in glomerulonephritis are discussed.
CHANGES OF MAXIMAL POWER OUTPUT OF LOWER EXTREMITY DURING A DECATHLON
Authors: P Edouard, JB Morin, P Samozino
Journal: British Journal of Sports Medicine (2014)

Background In decathlon, a higher injury risk over other Athletics disciplines has been reported. It may be caused by neuromuscular fatigue, which may be induced by repeated maximal efforts over the two days of competition. Objectives To determine the change in lower extremity power output over the course of a decathlon in order to better define/understand 1) the functional demands represented by decathlon, 2) the muscular mechanical capabilities determining decathlon performance, and 3) their potential relationships with injury risk factors. Design Cross-sectional controlled study. Setting Field conditions during the 2010 French National Decathlon Championships. Participants 6 national-level athletes and 11 representative control subjects. Main outcome measures The change in lower extremity power output, and its force and velocity components, was tested on the basis of maximal squat jump and cycling sprint measurements, at the beginning and end of the two days of competition. Results No differences in squat jump and cycling sprint values were found between each testing time (P&gt;.05), while significant lower squat jump values for control participants were reported at the second day beginning (P&lt;.05). Conclusions No significant changes in lower extremity muscle power output were reported over the course of a decathlon, suggesting no substantial neuromuscular fatigue was induced by two days of decathlon competition. We can therefore reasonably assume that the accumulation of fatigue (and/or neuromuscular fatigue, if any) does not play a major role in injury risk in decathlon. Higher injury risk reported in decathlon may be due to the sum of the injury risks of the 10 events. Our study could be considered as a pilot study, and future studies should be done to confirm these preliminary results.
Global Fund suspends grants to Mali in new drive against fraud
Authors: P. Moszynski
Journal: BMJ (2010)

The Global Fund to Fight AIDS, Tuberculosis and Malaria has suspended funding for two malaria grants in Mali with immediate effect and has terminated a third grant for tuberculosis after it found “evidence of misappropriation and unjustified expenditure.”

The fund said that the government of Mali has condemned the embezzlement of funds and is working with it “to solve problems and ensure that grant activities can resume as soon as possible.” It says that management of the suspended grants will be transferred to a new principal recipient.

In a …
Preventing Rh immunisation
Authors: E A Letsky, M De Silva
Journal: BMJ (1994)

Preventing Rh immunisationMuch scope for improvementWithout prophylaxis, about one in six Rh negative women who deliver a Rh positive infant will develop anti-D antibodies from fetomaternal haemorrhage occurring either during pregnancy or at delivery.'Since the introduction in 1969 of anti-D immunoglobulin given after delivery the incidence of haemolytic disease of the newborn due to anti-D antibodies has plummeted.In Britain, however, the rate of RhD sensitisation is still unacceptably high, at around 1 5%; in other words, more than 1000 Rh negative women each year develop anti-D antibodies in association with the delivery of a Rh positive infant.No universal policy exists for postnatal prophylaxis.The standard dose of anti-D immunoglobulin and whether tests are undertaken to assess the size of the fetomaternal haemorrhage vary in different countries.For example, 300 ,ug anti-D immunoglobulin is the standard dose in the
The Management of Mitral Valve Prolapse
Authors: Bruce M. Romanic
Journal: JAMA (1986)

<h3>To the Editor.—</h3> I found Dr Jeresaty's<sup>1</sup>recent update on mitral valve prolapse in the Aug 9 issue of<i>JAMA</i>very useful. I would like to comment, however, on the use of antiplatelet therapy in these patients. As was mentioned, mitral valve prolapse probably plays a role in cerebral ischemia, at least in patients younger than 45 years of age.<sup>2</sup>I would also like to point to a study concerning platelet coagulant hyperactivity in patients with mitral valve prolapse.<sup>3</sup>In this study, 100% of patients with mitral valve prolapse and thromboembolic complications showed platelet coagulant hyperactivity, as did 58% of patients with mitral valve prolapse but no history of thromboembolic or visual manifestations. This compared with only 6% of a control group without mitral valve prolapse showing platelet coagulant hyperactivity. Given this information, antiplatelet prophylaxis appears reasonable, especially in those patients who express concern, verbally or nonverbally, about
Potential for Genetics to Promote Public Health
Authors: Chris Carlsten, Wylie Burke
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-564 Implications of the local hemodynamic forces on vessel wall responses following drug-eluting bioresorbable vascular scaffold implantation: an optical coherence tomography analysis
Authors: Christos Bourantas, Michail I. Papafaklis, Kotsia Anna, Vasim Farooq, Cécile Dorange, Dimitrios I. Fotiadis, Josep Gomez Lara, Lampros Michalis, Takashi Muramatsu, Katerina K. Naka, Yoshinobu Onuma, Richard Rapoza, Hector M. Garcia-Garcia, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2013)
Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies
Authors: Anneke I. den Hollander, Aaron Black, Jean Bennett, Frans P.M. Cremers
Journal: Journal of Clinical Investigation (2010)

Nonsyndromic recessive retinal dystrophies cause severe visual impairment due to the death of photoreceptor and retinal pigment epithelium cells. These diseases until recently have been considered to be incurable. Molecular genetic studies in the last two decades have revealed the underlying molecular causes in approximately two-thirds of patients. The mammalian eye has been at the forefront of therapeutic trials based on gene augmentation in humans with an early-onset nonsyndromic recessive retinal dystrophy due to mutations in the retinal pigment epithelium–specific protein 65kDa (RPE65) gene. Tremendous challenges still lie ahead to extrapolate these studies to other retinal disease–causing genes, as human gene augmentation studies require testing in animal models for each individual gene and sufficiently large patient cohorts for clinical trials remain to be identified through cost-effective mutation screening protocols.
Choice of Revascularization Strategy for Patients With Coronary Artery Disease
Authors: René Prêtre
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pruritus Associated with Cholestatic Liver Disease
Authors: Y. Horsmans
Journal: Annals of Internal Medicine (1996)

Letters15 October 1996Pruritus Associated with Cholestatic Liver DiseaseY. Horsmans, MD and A.P. Geubel, MDY. Horsmans, MDLouvain Medical School, 1200 Brussels, BelgiumSearch for more papers by this author and A.P. Geubel, MDLouvain Medical School, 1200 Brussels, BelgiumSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-125-8-199610150-00032 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Pruritus is a frequent complication of cholestatic liver disease. The disorder may be disabling, especially in patients with primary biliary cirrhosis. The mechanism of pruritus remains unknown. Treatments proposed to relieve pruritus include bile acid-sequestering resin, phenobarbital, rifampicin, and naloxone [1, 2]. All of these drugs are associated with a highly variable response rate, with some patients having a poor or no response. We report an impressive effect of grapefruit juice in the treatment of severe pruritus.Five patients with primary biliary cirrhosis were treated using grapefruit juice (600 mL daily) to relieve severe pruritus. All patients ...References1. Jones EA, Bergasa NV. The pruritus of cholestasis. From bile acids to opiate agonists. Hepatology. 1990; 11:884-7. Google Scholar2. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology. 1992; 102:544-9. Google Scholar3. Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and its bitter principal, naringenin on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol. 1993; 35:431-6. Google Scholar4. Merkel U, Sigusch H, Hoffman A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur J Clin Pharmacol. 1994; 46:175-7. Google Scholar5. Yee GC, Stanley DL, Pessa LJ, Dalla Costa T, Beltz SE, Ruiz J, et al. Effect of grapefruit juice on blood cyclosporin concentration. Lancet. 1995; 345:955-6. Google Scholar Author, Article, and Disclosure InformationAuthors: Y. Horsmans, MD; A.P. Geubel, MDAffiliations: Louvain Medical School, 1200 Brussels, Belgium PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byComplications of CholestasisPruritus in Primary Biliary Cirrhosis: Pathogenesis and TherapyComplications of Cholestasis 15 October 1996Volume 125, Issue 8Page: 701KeywordsBileDrugsEnzyme metabolismEnzymesFlavonoidHepatitis ALiverLiver diseasesPrimary biliary cirrhosisPruritus ePublished: 15 August 2000 Issue Published: 15 October 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Modern Clinical Psychiatry
Authors: H. Keith Fischer
Journal: JAMA (1973)

This eighth edition is the first not to bear the name of Arthur B. Noyes, the original and sole author of the first four editions. Lawrence C. Kolb alone takes over its name after being sole author since the 1963 edition (sixth edition). A major organizational change reorders and redesignates chapters to conform to the new Eighth International Classification of Disease. The basic format, at times the language, illustrative case reports, and the significant theoretical and phenomenological material are retained. However, updated and expanded clinical information appears in every chapter and in the bibliography. A chapter on special symptoms is added, and with those on behavior disorders of childhood and adolescence, and mental retardation, together offers a much expanded coverage of disorders of early life. Although the clinical base of psychoanalytic dynamic theory in personality development and conflict is the central functional concept, anatomical, biochemical, adaptational processes and mechanisms all